Interestingly, IL-4Rα blocking antibody dupilumab given in conjunction with PD-(L)1 ICB in NSCLC patients who had progressed on ICB alone reduced circulating Mo, expanded tumor-infiltrating CD8+ T cells, and in one out of six patients, drove a near-complete clinical response two months after treatment, advocating for its further clinical evaluation (143). This evidence concerns the gene CD8A and neoplasm.